Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

Yetzugo is a long-acting HIV-1 capsid inhibitor that reduces the risk of sexually acquired HIV in adults and adolescents.

What kind of uptake can Gilead Sciences expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) ...

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or ...

The FDA has approved Yeztugo for PrEP to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35kg.

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

Approval of first twice-yearly HIV pre-exposure prophylaxis was based on results from the Phase III PURPOSE 1 and PURPOSE 2 ...

Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...

The FDA has approved Yeztugo for PrEP to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35kg.

June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections.